The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
about
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsTCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsFostamatinib Disodium.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemiaThe establishment of a primary culture system of proximal tubule segments using specific markers from normal mouse kidneys.The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.The B-cell receptor signaling pathway as a therapeutic target in CLL.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLLEmerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signalingBiology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.The Syk kinase as a therapeutic target in leukemia and lymphoma.Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.Chronic lymphocytic leukemia: an update on biology and treatment.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.A novel retinoblastoma therapy from genomic and epigenetic analyses.EBV-related lymphomas: new approaches to treatment.
P2860
Q26744277-F6BBBF62-0D61-4570-B02A-24F9C4DF3690Q26764833-0EB23EF4-E00A-4533-940E-1411B4472B41Q26773053-E1E1D78F-C86E-4843-ABDE-F646DBEA091AQ26798062-7B204985-39D8-4BE9-A4FA-9AA2EC893BE3Q26859114-D5DF9966-D0D2-4E99-8439-F6B1340788A7Q28081162-B94808C8-D895-4BF6-82DB-A131A89EC930Q33405080-895F0E17-A9DB-41A3-8C46-2B1EE63C9DB2Q34020276-DC2DC8A4-7BE4-4ED2-A769-307DFD221027Q34029869-C43B5BA6-3006-48D6-85E5-284DF7DEAC79Q34081881-55A3CCCB-182C-4502-92B6-3EE39DEF3155Q35153215-531C4DDA-2BD3-48F9-991E-03E34BD1FF95Q35604063-52F3B596-90E1-47E4-ABD4-FD19D807E8BFQ35934092-8A36BC68-5FD7-4D81-A57F-1A83BD5B2BF8Q36133043-853A3960-716E-4762-B8A3-07508474F8E5Q36163034-7FF5D686-E34D-4CF8-9BAC-7AFED9900B02Q36404778-D94CA38A-52F8-46A6-9845-CF521C733B1EQ36462375-4BECAC5E-417A-4BA4-B479-D5788E3BC168Q36739295-70727E66-FAE2-40E1-A3F4-A1D6B1F8966FQ36782109-DB049A3C-BA35-4020-BC90-F13BC6AD3132Q36862781-1FCADFB9-D403-4889-97BA-49D8C39EA584Q37576591-F30949EB-B045-4F6E-8167-DDBF7F1D63D9Q37857853-4DEA2F4B-D620-4E62-8651-CBF097D37A49Q37866334-8C518E4F-EA2F-452B-9FEA-246C73CDBAC3Q37902948-2B7C551C-FFB8-450D-B73E-6CA422BA22C9Q37910914-86ADDD06-0CD4-43D1-8BF4-F54C4F65BB14Q38011765-5B264373-3378-45B3-998C-4226465AB78DQ38012179-57107EC8-EDE8-47DB-8C60-F9BC3206259BQ38046045-B806CF1F-2D76-46CB-945E-3DDAB0B030A7Q38101590-A8D069EC-4D85-468C-A986-BFE2E5324E1BQ38124120-F8476D38-4C08-4BDB-A778-D8BBC6F33E41Q38150876-2FFEC50C-5F73-4AE1-BA6B-7CACF0037CD4Q38189089-A3AA27D8-90A5-42EB-B36A-AF3EC2CC1D5CQ38362950-A02F4D00-ACD3-415A-BB27-811F425FFCEEQ38554422-A97C867F-F9C6-4B19-81AE-59D16D1B4CAEQ38766412-83A19C7D-D5A1-4F27-B692-7B2FF5784BC1Q38943877-26D13CFE-6950-483B-84D6-3D7021D68935Q38996766-EA28FA37-AD8A-44B4-BF5E-2B5575DA7B42Q39164486-4D350C5F-7D3F-42B2-9206-E22233C00D62Q39413689-AD5FDC53-1FDF-47FC-ABDF-338B6D40BA1BQ39441281-DC207ED4-3A8A-4445-BDD8-6A3E32B0BDB7
P2860
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The Syk inhibitor fostamatinib ...... ent B-cell receptor signaling.
@en
The Syk inhibitor fostamatinib disodium
@nl
type
label
The Syk inhibitor fostamatinib ...... ent B-cell receptor signaling.
@en
The Syk inhibitor fostamatinib disodium
@nl
prefLabel
The Syk inhibitor fostamatinib ...... ent B-cell receptor signaling.
@en
The Syk inhibitor fostamatinib disodium
@nl
P2093
P1433
P1476
The Syk inhibitor fostamatinib ...... ent B-cell receptor signaling.
@en
P2093
Emerald Perlas
Luca Laurenti
Mirza Suljagic
Pablo G Longo
Sara Bennardo
P304
P356
10.1182/BLOOD-2010-03-275180
P407
P577
2010-08-17T00:00:00Z